Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442258 | 0.85 | DDR2 (0.53) | KCNK3BRAFPDGFRB | |
| SCHEMBL10552148 | 0.82 | HTR2C (0.44) | RAB9A | |
| SCHEMBL5440393 | 0.81 | KCNK3 (0.51) | MAPTKCNK3LMNABRAFMEN1 | |
| SCHEMBL5438536 | 0.81 | MEN1 (0.48) | MAPTKCNK3LMNABRAFMEN1 | |
| SCHEMBL5436052 | 0.79 | MAPT (0.49) | MAPTKCNK3LMNABRAFMEN1 | |
| SCHEMBL5436375 | 0.79 | BRAF (0.50) | MAPTKCNK3LMNABRAFMEN1 | |
| SCHEMBL5435141 | 0.79 | BRAF (0.46) | MAPTKCNK3LMNABRAFMEN1 | |
| SCHEMBL5440471 | 0.79 | BRAF (0.63) | KCNK3BRAFMEN1KMT2AHTT | |
| SCHEMBL5442174 | 0.79 | PTGS1 (0.46) | MAPTKCNK3LMNABRAFMEN1 | |
| SCHEMBL5437554 | 0.78 | PTGS1 (0.46) | MAPTKCNK3LMNABRAFMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219183-A1 | Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | claimed |
| US-20070219183-A1 | Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219183-A1 | Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof | DPYD, DUT, TYMP | MAPT 3594/4885KCNK3 3374/4885LMNA 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.